Abstract
Neuroblastoma cell lines such as SH-SY5Y are the most frequently utilized models in neurodegenerative research, and their use has advanced the understanding of the pathology of neurodegeneration over the past few decades. In Alzheimer’s disease (AD), several pathogenic mutations have been described, all of which cause elevated levels of pathological hallmarks such as amyloid-beta (Aβ). Although the genetics of Alzheimer’s disease is well known, familial AD only accounts for a small number of cases in the population, with the rest being sporadic AD, which contains no known mutations. Currently, most of the in vitro models used to study AD pathogenesis only examine the level of Aβ42 as a confirmation of successful model generation and only perform comparisons between wild-type APP and single mutants of the APP gene. Recent findings have shown that the Aβ42/40 ratio in cerebrospinal fluid (CSF) is a better diagnostic indicator for AD patients than is Aβ42 alone and that more extensive Aβ formation, such as accumulation of intraneuronal Aβ, Aβ plaques, soluble oligomeric Aβ (oAβ), and insoluble fibrillar Aβ (fAβ) occurs in TgCRND8 mice expressing a double-mutant form (Swedish and Indiana) of APP, later leading to greater progressive impairment of the brain. In this study, we generated SH-SY5Y cells stably transfected separately with wild-type APP, the Swedish mutation of APP, and the Swedish and Indiana mutations of APP and evaluated the APP expression as well as the Aβ42/40 ratio in those cells. The double-mutant form of APP (Swedish/Indiana) expressed markedly high levels of APP protein and showed a high Aβ2/40 ratio compared to wild-type and single-mutant cells.
Similar content being viewed by others
References
Pulawski, W., Ghoshdastider, U., Andrisano, V., & Filipek, S. (2012). Ubiquitous Amyloids. Applied Biochemistry and Biotechnology, 166(7), 1626–1643.
Griffiths, A. J. F., Miller, J. H., Suzuki, D. T., Richard, C. L., & William, M. G. (2000). An introduction to genetic analysis (7th ed.). New York: W. H. Freeman https://www.ncbi.nlm.nih.gov/books/NBK21766/.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992). Mutation of the [beta]-amyloid precursor protein in familial Alzheimer's disease increases [beta]-protein production. Nature, 360, 672–674.
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991). A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science, 254, 97–99.
Goedert, M., & Spillantini, M. G. (2006). A century of Alzheimer's disease. Science, 314, 777–781.
Lewczuk, P., Lelental, N., Maler, J. M., Spitzer, P., & Kornhuber, J. (2014). Early diagnosis of Alzheimer's disease with the β-amyloid 42/40 CSF concentration ratio: analytical and clinical validation of two novel assays. The Journal of the Alzheimer's Association, 10, P799–P800.
Chishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., & French, J. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Journal of Biological Chemistry, 276, 21562–21570.
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid. Nature Genetics, 1, 345–347.
Kingston, R. E. (2001). Introduction of DNA into mammalian cells. Current Protocol in Molecular Biology, John Wiley & Sons Inc, DOI. doi:10.1002/0471142727.mb0900s64.
Rose, J. K. (2001). Optimization of transfection. Current Protocols in Neuroscience. John Wiley & Sons Inc, doi: 10.1002/0471142301.nsa01bs01.
Washbourne, P., & McAllister, A. K. (2002). Techniques for gene transfer into neurons. Current Opinion in Neurobiology, 12, 566–573.
Kim, S. W., Ogawa, T., Tabata, Y., & Nishimura, I. (2004). Efficacy and cytotoxicity of cationic-agent–mediated nonviral gene transfer into osteoblasts. Journal of Biomedical Materials Research Part A, 71, 308–315.
Soenen, S. J., Brisson, A. R., & De Cuyper, M. (2009). Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials, 30, 3691–3701.
Lappalainen, K., Jääskeläinen, I., Syrjänen, K., Urtti, A., & Syrjänen, S. (1994). Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharmaceutical Research, 11, 1127–1131.
Li, M., Husic, N., Lin, Y., Christensen, H., Malik, I., Mciver, S., Lapash Daniels, C. M., Harris, D. A., Kotzbauer, P. T., Goldberg, M. P., & Snider, B. J. (2010). Optimal promoter usage for Lentiviral vector-mediated transduction of cultured central nervous system cells. Journal of Neuroscience Methods, 189(1), 56–64.
Eisenberg, D., & Jucker, M. (2012). The amyloid state of proteins in human diseases. Cell, 148, 1188–1203.
Masters, C. L., & Selkoe, D. J. (2012). Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2, a006262.
Nalivaeva, N. N., & Turner, A. J. (2013). The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Letters, 587, 2046–2054.
Selkoe, D. J. (2000). Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β-Protein. Annals of the New York Academy of Sciences, 924, 17–25.
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The C-terminus of the β protein is critical in Amyloidogenesisa. Annals of the New York Academy of Sciences, 695, 144–148.
Suarez-Calvet, M., Belbin, O., Pera, M., Badiola, N., Magrane, J., Guardia-Laguarta, C., Munoz, L., Colom-Cadena, M., Clarimon, J., & Lleo, A. (2014). Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Abeta production. Journal of Neurochemistry, 128, 330–339.
Hecimovic, S., Wang, J., Dolios, G., Martinez, M., Wang, R., & Goate, A. M. (2004). Mutations in APP have independent effects on Aβ and CTFγ generation. Neurobiology of Disease, 17, 205–218.
Acknowledgements
This study was financially supported by Universiti Kebangsaan Malaysia Grants DIP/2013/003 and FF-2015-025 and Ministry of Higher Education Grant LRGS/BU/2012/UKM-UKM/K/04.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pahrudin Arrozi, A., Shukri, S.N.S., Wan Ngah, W.Z. et al. Evaluation of the Expression of Amyloid Precursor Protein and the Ratio of Secreted Amyloid Beta 42 to Amyloid Beta 40 in SH-SY5Y Cells Stably Transfected with Wild-Type, Single-Mutant and Double-Mutant Forms of the APP Gene for the Study of Alzheimer’s Disease Pathology. Appl Biochem Biotechnol 183, 853–866 (2017). https://doi.org/10.1007/s12010-017-2468-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-017-2468-6